证券代码：002001 证券简称：新和成 公告编号：2024-001 浙江新和成股份有限公司 关于控股股东增持公司股份计划的进展公告 新和成控股集团有限公司保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 浙江新和成股份有限公司（以下简称"公司"）于 2023 年 10 月 27 日披露的 《关于控股股东增持公司股份计划的公告》（公告编号：2023-064），公司控股股 东新和成控股集团有限公司（以下简称"新和成控股公司"）自通知之日起 6 个 月内通过深圳证券交易所交易系统允许的方式（包括但不限于集中竞价、大宗交 易等）增持公司股份，拟增持股份的金额不低于人民币 2 亿元，不超过人民币 3 亿元。本次增持计划不设价格区间，将根据公司股票价格波动情况及资本市场整 体趋势，逐步实施增持计划。 根据《深圳证券交易所上市公司自律监管指引第 10 号——股份变动管理》 等有关规定，截至本公告日，公司控股股东增持公司股份计划时间已过半，现将 有关增持计划进展情况公告如下： 一、计划增持主体的基本情况 1、计 ...

Group 1: Company Overview - Zhejiang Xinhengcheng Co., Ltd. is a national high-tech enterprise primarily engaged in the production and sales of nutritional products, flavors and fragrances, high polymer new materials, and raw pharmaceuticals [1][2]. - The company has established four major production bases in Zhejiang, Shandong, and Heilongjiang, with the Zhejiang Xinchang base being the core of its health industry [1][2]. Group 2: Financial Performance - In the first three quarters of 2023, the company achieved a total revenue of CNY 11.012 billion and a net profit attributable to shareholders of CNY 2.101 billion [2]. Group 3: Product Development Plans - The solid methionine production plan aims for an annual output of 300,000 tons, with the first phase of 50,000 tons completed in 2017 [2]. - The company is also developing a liquid methionine project in collaboration with Sinopec, targeting an annual production capacity of 180,000 tons [2]. Group 4: Product Strategy - The company focuses on four main sectors: nutritional products, flavors and fragrances, new materials, and raw pharmaceuticals, aiming to enhance its product lines and develop new growth points [3]. - In the nutritional products sector, the company plans to strengthen its vitamin series through both synthetic and fermentation processes [3]. Group 5: Competitive Advantages - The company invests over 5% of its revenue in R&D annually, establishing a comprehensive innovation system that emphasizes key technologies for economic development [3]. - Collaboration with renowned universities and research institutions enhances the company's technological capabilities and product development [3]. Group 6: Future Projects - New projects in 2024 will continue to focus on nutritional products, flavors and fragrances, new materials, and raw pharmaceuticals, with all sectors expected to launch new products [4].

证券代码：002001 证券简称：新和成 公告编号：2023-066 浙江新和成股份有限公司 关于控股股东持股变动超过 1%暨增持公司股份计划的进展公告 新和成控股集团有限公司保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 浙江新和成股份有限公司（以下简称"公司"）于 2023 年 10 月 27 日披露的 《关于控股股东增持公司股份计划的公告》（公告编号：2023-064），公司控股股 东新和成控股集团有限公司（以下简称"新和成控股公司"）自通知之日起 6 个 月内通过深圳证券交易所交易系统允许的方式（包括但不限于集中竞价、大宗交 易等）增持公司股份，拟增持股份的金额不低于人民币 2 亿元，不超过人民币 3 亿元。本次增持计划不设价格区间，将根据公司股票价格波动情况及资本市场整 体趋势，逐步实施增持计划。现将相关增持进展情况披露如下： 一、计划增持主体的基本情况 1、计划增持主体名称：新和成控股集团有限公司 2、本次增持计划实施前，新和成控股公司直接持有公司股份 1,521,362,525 股 ...

证券代码：002001 证券简称：新和成 公告编号：2023-065 浙江新和成股份有限公司 关于第三期员工持股计划出售完毕暨终止的公告 浙江新和成股份有限公司（以下简称"公司"）于 2020 年 10 月 26 日召开 第八届董事会第三次会议、第八届监事会第二次会议，于 2020 年 11 月 11 日召 开 2020 年第二次临时股东大会，审议通过《浙江新和成股份有限公司第三期员 工持股计划（草案）及其摘要》等员工持股计划相关议案，同意公司实施第三期 员工持股计划。具体内容详见公司于 2020 年 10 月 27 日、2020 年 11 月 12 日在 指定信息披露媒体及巨潮资讯网（http://www.cninfo.com.cn）上刊登的公告。 公司于 2022 年 10 月 31 日召开第八届董事会第十四次会议，审议通过《关 于第三期员工持股计划存续期展期的议案》，同意公司第三期员工持股计划存续 期延长 12 个月，即存续期由 2020 年 11 月 11 日至 2022 年 11 月 10 日调整为 2020 年 11 月 11 日至 2023 年 11 月 10 日，其他内容不做变更。具体内容详见 ...

Financial Performance - The company's operating revenue for Q3 2023 was CNY 3,593,667,979.82, a decrease of 2.74% compared to CNY 3,694,978,168.41 in the same period last year[3] - Net profit attributable to shareholders for Q3 2023 was CNY 576,061,979.82, down 22.48% from CNY 743,000,000 in the previous year[3] - The basic earnings per share for Q3 2023 was CNY 0.20, a decline of 23.08% compared to CNY 0.26 in the same period last year[4] - Operating profit for Q3 2023 was CNY 2,507,878,228.28, down 29.3% from CNY 3,551,143,658.19 in the same period last year[20] - The total profit for the third quarter was approximately ¥2.51 billion, a decrease of 29.3% from ¥3.55 billion in the same period last year[22] - The net profit for the third quarter was approximately ¥2.12 billion, down 29.9% from ¥3.02 billion year-over-year[22] - The total comprehensive income for the third quarter was approximately ¥2.15 billion, down from ¥3.06 billion year-over-year[22] - Basic and diluted earnings per share for the third quarter were both ¥0.68, down from ¥0.98 in the same period last year[22] Assets and Liabilities - The company's total assets at the end of Q3 2023 were CNY 38,774,279,496.58, reflecting a 1.32% increase from CNY 38,267,625,155.83 at the beginning of the year[4] - Total assets as of September 30, 2023, amounted to CNY 38,774,279,496.58, an increase from CNY 38,268,063,792.50 at the beginning of the year[19] - The company's total liabilities decreased slightly to CNY 14,466,681,832.00 from CNY 14,605,894,699.41 at the beginning of the year[19] - Current assets decreased to CNY 12,361,191,565.93 from CNY 14,111,200,051.59 at the start of the year, reflecting a decline of 12.36%[18] - Long-term borrowings increased to CNY 6,772,092,279.53 from CNY 5,273,637,508.87, representing a growth of 28.38%[19] Cash Flow - The net cash flow from operating activities was approximately ¥2.63 billion, an increase of 3.9% compared to ¥2.53 billion in the previous year[23] - The cash flow from investing activities resulted in a net outflow of approximately ¥2.87 billion, worsening from a net outflow of ¥1.64 billion in the same period last year[24] - The cash flow from financing activities showed a net outflow of approximately ¥293 million, compared to a net inflow of ¥344 million in the previous year[24] - The company received cash from operating activities totaling approximately ¥12.82 billion, a decrease from ¥13.21 billion year-over-year[23] - The company paid approximately ¥3.14 billion in debt repayment during the financing activities, an increase from ¥2.35 billion in the previous year[24] Investments and Expenses - Research and development expenses for Q3 2023 were CNY 630,879,477.56, up from CNY 600,093,376.48 in Q3 2022, indicating a year-over-year increase of 5.15%[20] - Long-term equity investments increased by 59.75% compared to the beginning of the year, attributed to increased investments in joint ventures[7] - The company experienced a 729.26% increase in asset impairment losses year-on-year, primarily due to market price fluctuations of products[9] - Cash flow from investment activities decreased by 74.84% year-on-year, mainly due to reduced financial management of raised funds and increased fixed asset expenditures[10] Shareholder Information - The total number of common shareholders at the end of the reporting period is 116,509, with the top 10 shareholders holding 49.22% of the shares[11] - New and Cheng Holdings Group Co., Ltd. holds 1,521,362,525 shares, accounting for 49.22% of the total shares[11] - The top 10 shareholders include various entities, with the largest being New and Cheng Holdings Group Co., Ltd. and Hong Kong Central Clearing Limited[11] - The fourth employee stock ownership plan purchased 29,528,181 shares, representing 0.9553% of the total share capital, at an average price of approximately 16.2368 RMB per share[13] - The total amount for the stock purchase under the fourth employee stock ownership plan is 479,442,157.08 RMB[13] Corporate Governance - The company completed the election of the ninth board of directors and the ninth supervisory board on September 19, 2023[16] - The company appointed Hu Baifan as chairman and Hu Bochuan as vice chairman of the ninth board of directors[16] Fundraising Activities - As of September 30, 2023, the balance of raised funds is 59,770.48 million RMB, including bank deposits and investment income[15] - The company has utilized 123,683.41 million RMB of the raised funds from January to September 2023, with a cumulative investment of 501,503.20 million RMB[15] - The company’s fundraising project has been verified by Tianjian Accounting Firm, confirming the net amount raised is 486,707.55 million RMB[15]

证券代码：002001 证券简称：新和成 公告编号：2023-061 浙江新和成股份有限公司 第九届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新和成股份有限公司（以下简称"公司"）第九届董事会第二次会议于 2023 年 10 月 20 日以电子邮件方式发出会议通知，于 2023 年 10 月 25 日以现场 结合通讯方式召开。应出席董事 11 名，实际出席董事 11 名，符合《公司法》和 《公司章程》的规定。会议经表决形成决议如下： 一、会议以 11 票同意，0 票反对，0 票弃权审议通过《2023 年第三季度报 告》的议案； 《2023 年第三季度报告》中的财务信息在提交董事会审议前已经公司审计 委员会审议通过；《2023 年第三季度报告》全文详见公司同日在指定信息披露媒 体及巨潮资讯网（http://www.cninfo.com.cn）刊登的公告。 二、会议以 7 票同意，0 票反对，0 票弃权审议通过《关于 2023 年度日常关 联交易预计调整的议案》；关联董事胡柏藩、胡柏剡、石观群、王学闻回避表决， 独立董事就该事项 ...

证券代码：002001 证券简称：新和成 公告编号：2023-064 浙江新和成股份有限公司 特别提示： 浙江新和成股份有限公司（以下简称"公司"）于 2023 年 10 月 26 日接到 公司控股股东新和成控股集团有限公司（以下简称"新和成控股公司"）的通知， 基于对公司未来持续稳定发展的信心以及对公司价值的认可，提升投资者信心， 新和成控股公司计划自通知之日起 6 个月内通过深圳证券交易所交易系统允许 的方式（包括但不限于集中竞价、大宗交易等）增持公司股份，拟增持股份的金 额不低于人民币 2 亿元，不超过人民币 3 亿元。本次增持计划不设价格区间，将 根据公司股票价格波动情况及资本市场整体趋势，逐步实施增持计划。现将相关 增持方案披露如下： 4、新和成控股公司在本次公告前 6 个月内，不存在减持公司股份情况。 一、计划增持主体的基本情况 1、计划增持主体名称：新和成控股集团有限公司 2、本次增持计划实施前，新和成控股公司直接持有公司股份 1,521,362,525 股，占公司总股本的 49.22%。实际控制人及一致行动人胡柏藩先生直接持有公 司股份 13,922,998 股，占公司总股本的 0.45%；一 ...

证券代码：002001 证券简称：新和成 公告编号：2023-063 浙江新和成股份有限公司 关于 2023 年度日常关联交易预计调整的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新和成股份有限公司（以下简称"公司"）于 2023 年 10 月 25 日召开的 第九届董事会第二次会议审议通过《关于 2023 年度日常关联交易预计调整的议 案》，关联董事胡柏藩、胡柏剡、石观群、王学闻进行了回避表决。根据《深圳 证券交易所股票上市规则》《公司章程》及公司《关联交易决策制度》等有关规 定和审批权限，本次关联交易由公司董事会审议批准，无需提交股东大会审议。 单位：人民币万元 一、调整日常关联交易基本情况 根据公司和关联方实际生产经营情况，为更加准确反映公司与关联方 2023 年度日常关联交易情况，拟对预计金额做出合理调整。因公司新项目建设需要， 公司对关联方浙江德力装备有限公司（以下简称"德力装备"）容器设备需求相 应增加，预计关联采购额度增加 2,400 万元。2023 年度日常关联交易预计总额由 62,972.73 万元调整为 65,372.73 万 ...

浙江新和成股份有限公司九届二次董事会 独立董事相关独立意见 根据《公司法》《上市公司独立董事管理办法》《深圳证券交易所股票上市规 则》等法律法规及《公司章程》的有关规定，作为浙江新和成股份有限公司（以 下简称"公司"）第九届董事会独立董事，我们就公司第九届董事会第二次会议 审议《关于 2023 年度日常关联交易预计调整的议案》相关事项发表独立意见如 下： 1、独立董事事前认可情况 我们认为：公司调整 2023 年度与关联方发生的日常关联交易预计系公司正 常生产经营所需，上述关联交易遵守了客观、公正、公平的交易原则；关联董事 进行回避表决，其决策程序合法、有效；定价原则公允，未发现损害公司和股东 利益的情况，我们对此无异议。 独立董事：季建阳、沈玉平、万峰、王洋 2023 年 10 月 27 日 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》及《公司 章程》等有关规定，我们作为公司的独立董事，现就第九届董事会第二次会议之 《关于 2023 年度日常关联交易预计调整的议案》，发表事前审查意见： 公司在会议召开前提交了 202 ...

Group 1: Company Performance and Projects - The company's methionine project is currently in a phased trial run, showcasing a strong profit margin maintained by Shandong Amino Acid Company since 2005 [1] - The company has developed a fully autonomous, large-scale, green, and integrated solid methionine production facility, overcoming key foreign technologies since 2017 [1] - The demand for vitamin products is recovering, with expectations for price increases as downstream aquaculture profitability improves [2] Group 2: Strategic Development and Innovation - The company adheres to an innovation-driven development strategy, focusing on "chemicals+" and "biological+" as its main strategic directions [2] - Future growth will stem from integrated, series, and collaborative development strategies, enhancing research and application service capabilities [2] - The company plans to strengthen cost control across production, supply, sales, research, and finance to improve product competitiveness [2] Group 3: Financial Planning and Shareholder Returns - The company will arrange capital expenditure plans based on project investment situations, maintaining a stable profit distribution policy and cash dividend plan to reward shareholders [2] - High capital expenditures and dividends have been consistent in recent years, reflecting the company's commitment to investor trust and support [2]